CTL Differentiation Factor, Interleukin 6 (Interferon, Beta 2), HSF, B-cell stimulatory factor 2, Interferon beta-2, IL6, IFNB2, IL-6, Interleukin-6, Interleukin 6, Hybridoma Growth Factor, IFN-Beta-2, BSF-2, CDF, B-Cell Differentiation Factor, Interferon, Beta 2, Interleukin BSF-2, BSF2, HGF

KO Status

RenMab: In Vitro

Drug Information

Launched drugs: 5
Drugs in clinical trials: 18
Latest Research Phase: Approved

Drug Name





Clinical Trials

Luminol sodium



Selvim, Metrio

Coronavirus Disease 2019 (COVID-19), Immune System Diseases, Psoriasis


NSC-66847, NSC-527179, K-17, VP-02


Celgene Corp

HIV Infections, Spondylitis, Ankylosing, Myelodysplastic Syndromes, Idiopathic Pulmonary Fibrosis, Multiple Myeloma, HIV Wasting Syndrome, Erythema Nodosum, Leprosy, Lepromatous, Carcinoma, Hepatocellular


IMID-4047, CDC-394, CC-4047, IMiD-1


Celgene Corp

Medulloblastoma, Bone Marrow Neoplasms, Lymphoma, B-Cell, Solid tumours, Scleroderma, Systemic, Lymphoma, Large B-Cell, Diffuse, Hodgkin Disease, Multiple Myeloma, Lung Diseases, Interstitial, Central Nervous System Neoplasms, Sarcoma, Prostatic Neoplasms, Lymphoma, Follicular, Primary Myelofibrosis, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Sarcoma, Kaposi, Anemia, Sickle Cell


cCLB-8, CNTO-328


Johnson & Johnson

Respiratory Tract Infections, Ovarian Neoplasms, Head and Neck Neoplasms, Pneumonia, Carcinoma, Renal Cell, Smoldering Multiple Myeloma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Multiple Myeloma, Lung Diseases, Respiratory Distress Syndrome, Adult, Monoclonal Gammopathy of Undetermined Significance, Multicentric Castleman's Disease (MCD), Prostatic Neoplasms, Neoplasms, Plasma Cell, Colorectal Neoplasms, Castleman Disease, Lymphoma, Non-Hodgkin, Lung Neoplasms


IMID-5013, CDC-5013, CDC-501, CC-5013, IMiD-3, ENMD-0997


Celgene Corp

Leukemia, Myeloid, Lymphoma, B-Cell, Marginal Zone, Hematologic Diseases, Lymphoma, T-Cell, Peripheral, Solid tumours, Lymphoma, B-Cell, HIV Infections, Anemia, Paraproteinemias, Myelodysplastic Syndromes, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, Large B-Cell, Diffuse, Blood Protein Disorders, Smoldering Multiple Myeloma, Multiple Myeloma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Prostatic Neoplasms, Reflex Sympathetic Dystrophy, Radiculopathy, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin, Thrombocytopenia, Lymphoma, Waldenstrom Macroglobulinemia, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Melanoma, Carcinoma, Non-Small-Cell Lung, Crohn Disease, Complex Regional Pain Syndromes

Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences)



Prometic Life Sciences

Neoplasm Recurrence, Local, Urinary Bladder Neoplasms, Carcinoma in Situ


BA-003, CNTO-136


Glaxosmithkline Plc, Janssen Global Services Llc

Giant Cell Arteritis, Depressive Disorder, Major, Coronavirus Disease 2019 (COVID-19), Arthritis, Rheumatoid, Neoplasms, Lupus Erythematosus, Cutaneous, Lupus Nephritis, Polymyalgia Rheumatica, Lupus Erythematosus, Systemic, Asthma



Phase 3 Clinical

Promore Pharma

Tissue Adhesions, Post-surgical adhesions, Cicatrix


CDP-6038, Anti-IL6-UCB

Phase 3 Clinical


Coronavirus Disease 2019 (COVID-19), Arthritis, Rheumatoid, Arthritis, Crohn Disease


ALD-518, ALD518-003, BMS-645429, BMS-945429

Phase 3 Clinical

Alder Biopharmaceuticals

Anemia, Graft vs Host Disease, Arthritis, Rheumatoid, Fatigue, Rejection of organ transplantation, Arthritis, Psoriatic, Inflammation, Cachexia, Carcinoma, Non-Small-Cell Lung, Crohn Disease, Stomatitis





SorLA in Interleukin-6 Signaling and Turnover

Larsen J.V., Petersen C.M.,

Mol. Cell. Biol. 37:0-0(2017)

Targeting Interleukin-6 Signaling in Clinic

Kang S., Tanaka T., Narazaki M., Kishimoto T.,

Immunity 50:1007-1023(2019)

Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium

Ming J.E., Cernetti C., Steinman R.M., Granelli-Piperno A.,

J. Mol. Cell. Immunol. 4:203-211(1989)

Marked cell-type-specific differences in glycosylation of human interleukin-6

May L.T., Shaw J.E., Khanna A.K., Zabriskie J.B., Sehgal P.B.,

Cytokine 3:204-211(1991)

Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond

Breton J., la Fiura A., Bertolero F., Orsini G., Valsasina B., Ziliotto R., de Filippis V., Polverino de Laureto P., Fontana A.,

Eur. J. Biochem. 227:573-581(1995)

Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor

Clogston C.L., Boone T.C., Crandall B.C., Mendiaz E.A., Lu H.S.,

Arch. Biochem. Biophys. 272:144-151(1989)

Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6

Luetticken C., Kruettgen A., Moeller C., Heinrich P.C., Rose-John S.,

FEBS Lett. 282:265-267(1991)

Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6

Steensberg A., van Hall G., Osada T., Sacchetti M., Saltin B., Klarlund Pedersen B.,

J. Physiol. (Lond.) 529:237-242(2000)

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis

Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., Nishimoto N.,

Arthritis Rheum. 48:1521-1529(2003)

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T.,

J. Clin. Invest. 113:1271-1276(2004)